|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| PSMAfore Trial: Lutetium PSMA's Impact on mCRPC Quality of Life |
| Karim Fizazi, MD, Ph.D. |
| Alicia Morgans interviews Karim Fizazi about the updated survival and quality of life data from the PSMAfore trial. The study compares lutetium PSMA to second-line AR pathway inhibitors in metastatic castration-resistant prostate cancer patients who have progressed after one AR pathway inhibitor. |
|
|
|
|
|
|
|
|
|
|
|
| PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer |
Elena Castro, MD, Ph.D.
Elena Castro and Alicia Morgans discuss the use of PARP inhibitors and their combinations in advanced prostate cancer. They discuss data from the TRITON3, TALAPRO-2, and PROpel studies that help to fill in gaps in the current understanding. |
|
|
|
|
|
|
|
|
|
|
| 2024 NCCN Guidelines Update: Metastatic Castration-Resistant Prostate Cancer Treatment |
Rashid Sayyid, MD, MSc, and Zach Klaassen, MD, MSc
Rashid Sayyid and Zachary Klaassen discuss the 2024 updates to the NCCN guidelines for metastatic castration-resistant prostate cancer treatment. They review the current management algorithm, emphasizing the importance of confirming castrate status and proper staging. |
|
|
|
|
|
|
|
|
|
|
| Real-World Utilization Patterns of Radium-223 in Metastatic Prostate Cancer in the United States: An Administrative Claims Database Study
|
| Amit Raval, Ph.D.
|
| This real-world study examined the use of radium-223 in men with metastatic castration-resistant prostate cancer. It found that nearly half of the patients completed at least 5 cycles, with higher completion rates associated with combination therapy and longer survival prospects. The findings suggest the importance of early radium-223 treatment to enhance completion and potentially improve outcomes.
|
|
|
|
|
|
| The Current State of Treatment Implementation for mCRPC in North America
|
| Rashid Sayyid, MD, MSc, and Zachary Klaassen, MD, MSc |
| There have been significant advances in the mCRPC treatment landscape with the emergence and approval of numerous agents in this disease space. In this Center of Excellence article, Rashid Sayyid and Zachary Klaassen discuss the current state of treatment utilization for mCRPC patients in North America and provide a contemporary approach to the management of mCRPC patients who may have received treatment intensification in the metastatic hormone-sensitive setting.
|
|
|
|
|
|
| Unlocking Combination Therapy for mCRPC |
| Kim Chi, MD |
| Kim Chi discusses combination therapies for mCRPC, focusing on two key studies: CONTACT-2 and BRCAAway. CONTACT-2 evaluated cabozantinib and atezolizumab versus second-line hormonal therapy, showing a modest improvement in radiographic progression-free survival but no significant overall survival benefit. The BRCAAway trial explored the combination of PARP inhibitors and androgen receptor inhibitors in patients with HRR mutations, demonstrating a significant benefit in progression-free survival, particularly in BRCA2-mutated cancers, supporting the upfront use of these combinations as first-line therapy. |
|
|
|
|
|
|
|
|
|
|
| The Best Use of PARP Inhibitors in mCRPC |
| Joaquin Mateo, MD |
| Joaquin Mateo discusses the use of PARP inhibitors in mCRPC, emphasizing their efficacy in BRCA1/2 mutated cancers. He notes that these mutations are linked to poor prognosis but show high sensitivity to PARP inhibitors, regardless of whether the mutation is germline or somatic. While combinations of PARP inhibitors with ARPIs show promise, there’s a need for clinical trials to determine the best treatment approach, especially comparing combination versus sequential use of these therapies. |
|
|
|
|
|
|
|
|
|
|
